Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia Acquired von Willebrand syndrome represents a rare but significant complication of chronic lymphocytic leukemia. This patient achieved remission after treatment with venetoclax plus obinutuzumab.

#MedCase - Acquired von Willebrand syndrome represents a rare but significant complication of chronic lymphocytic #leukemia.

This patient achieved remission after treatment with #venetoclax plus #obinutuzumab.

👉 buff.ly/2QrQ0LE

#OncSky

Obinutuzumab significantly reduces disease activity in SLE Adding the anti-CD20 monoclonal antibody obinutuzumab to standard therapy for systemic lupus erythematosus significantly reduces disease activity.

#MedNews - Adding the anti-CD20 monoclonal antibody #obinutuzumab to standard therapy for systemic lupus erythematosus significantly reduces disease activity.

Full story 👉 buff.ly/lbBXfea

#RheumSky #SLE

Another B-Cell Drug for Lupus Hits the Mark Phase III results put obinutuzumab in line for approval

" #Obinutuzumab ( #Gazyva ) appears set to add systemic #lupus erythematosus ( #SLE ) to its list of approved indications, as results from a phase III trial showed it was significantly more effective than placebo, with no new safety concerns.": buff.ly/WWFikk5

via @medpagetoday.com
#BCell #MedSky

NICE backs Roche lupus drug that supports kidney function Roche's Gazyvaro, a drug that can restore kidney function in lupus nephritis, has been cleared for use by the NHS in England and Wales.

#NICE #Roche #lupusdrug #lupus #lupusnephritis #systemiclupuserythematosus #SLE #kidneyfunction #Gazyvaro #obinutuzumab #NHS #kidneydisease #autoimmunedisorder #antiCD20antibody #NICEdraftrecommendation #Clinicaltrials #MMF #phase3clinicaltrial #ALLEGORYtrial #LupusUK #HEOR
zurl.co/cH0ta

Thousands living with lupus offered hope from twice-yearly infusion Sign up for our newsletters and alerts

“[ #Obinutuzumab (Gazyvaro)] has been approved for #NHS use, offering new hope to the nearly 12,000 people in England living with #LupusNephritis.”: buff.ly/chsHoqF

from @NICEComms.bsky.social
#lupus #rheumatology #MedSky #autoimmune

NICE have recommended that a new treatment, obinutuzumab, can be used in combination with mycophenolate mofetil (MMF) to treat some patients with lupus nephritis in the NHS in England and Wales. 

👉 Learn more at https://lupusuk.org.uk/latest-news/

#Lupus #LupusNephritis #Obinutuzumab

Prospective Cohort Study of #Obinutuzumab in Rituximab-Resistant Primary #Membranous Nephropathy

#VisualAbstract by Denisse Arellano

www.kireports.org/article/S2468-0249(25)00...

Compared with #obinutuzumab monotherapy, the next-gen BTK inhibitor #zanubrutinib in combination with #obinutuzumab led to improved survival in patients with #FollicularLymphoma, resulting in ORRs of 70.3% vs. 44.4% and PFS of 22.1 vs. 10.3 months: https://ow.ly/qzV250XMMvj
#HemeSky #MedSky

#ASH25 The BCL2 inhibitor #sonrotoclax produced good responses in patients with treatment-naïve CLL/SLL when combined with #obinutuzumab, with ORRs of 89% across all patients and 93% at a 320 mg dose: https://ow.ly/M8uB50XF6zT
#HemeSky #MedSky

ロシュ、全身性エリテマトーデス（SLE）における抗CD20抗体オビヌツズマブ（ガザイバ）の第3相で主要評価項目を達成 | STELLANEWS.LIFE ロシュの抗CD20抗体オビヌツズマブ（ガザイバ）は、第3相ALLEGORY試験で全身性エリテマトーデス（SLE）の疾患活動性を有意に低下。主要評価項目および副次評価項目を達成し、安全性は既知の範囲内で新たな懸念は確認されなかった。

Roche’s Gazyva (obinutuzumab) meets all primary and secondary endpoints in Phase 3 ALLEGORY trial for systemic lupus erythematosus (SLE).

stellanews.life/technology_c...

#Gazyva #SLE #Lupus #Obinutuzumab #CD20 #AutoimmuneDiseases #Roche #ALLEGORYtrial

FDA approved #obinutuzumab #Gazyva for the treatment of #SLE #lupus nephritis when used with other standard therapies!

Complete renal responses: higher than standard therapies.

Studies show deep tissue B-cell depletion.

La vue du "condo" au CCJ de HMR aujourd'hui. #Cycle1Traitement4 #Obinutuzumab

#Cycle1 - 3e traitement #LLC #Obinutuzumab

MRD-Guided Treatment Approach Leads to Deep Remissions in CLL | ASH Clinical News | American Society of Hematology

Recent research indicates that MRD-guided time-limited treatment with #zanubrutinib, #venetoclax, and #obinutuzumab resulted in deep remissions in patients with previously treated #ChronicLymphocyticLeukemia, with a best uMRD rate of 85%: ow.ly/e16h50WwZ66
#HemeSky

Organising #Pneumonia in a Patient Following #Obinutuzumab for Follicular #Lymphoma
onlinelibrary.wiley.com/doi/10.1002/...

ICYMI: Richard Furie, MD, discussed the REGENCY trial of obinutuzumab in systemic lupus erythematosus and lupus nephritis. #obinutuzumab #lupusnephritis #lupus #nephrology #rheumatology www.docwirenews.com/post/regency...

Obinutuzumab Shows Promise for Lupus Nephritis in Phase 3 Trial | Docwire News In the phase 3 REGENCY trial, adding obinutuzumab to standard therapy for lupus nephritis led to better renal outcomes.

In the phase 3 REGENCY trial, adding #obinutuzumab to standard therapy for lupus nephritis demonstrated better renal outcomes. #lupusnephritis #nephrology #nephsky www.docwirenews.com/post/obinutu...

Vivek Subbiah: Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing - OncoDaily Vivek Subbiah: Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing / Active Lupus Nephritis, cancer, CLL, drug repurposing,

Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/science/2780...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lupus #Nephritis #Obinutuzumab

Obinutuzumab in Lupus Nephritis — NephJC This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not ...

This week (and tonight on #NephJC) we are discussing the REGENCY trial on #obinutuzumab in SLE specifically #lupus nephritis

summary from
@sayalibthakare.bsky.social
@dramiliflores.bsky.social & @nephroseeker.medsky.social

www.nephjc.com/news/regency...

#lupuschat #NephSky #RheumSky

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving stan...

➡️Up next
Join us Tues March 11th for discussing the new “regent”👑 in lupus nephritis! #Obinutuzumab (Rituximab’s 💪cousin) #REGENCY
www.nejm.org/doi/full/10....

👋 #NephJC #Tweetorial by @drpallaviprasad.bsky.social 🦋
Join us @ nephjc.bsky.social
See you soon! www.nephjc.com

🆕 #Obinutuzumab (Obi) in Lupus Nephritis: the REGENCY Trial

Phase 3 RCT: Obi vs PBO
🫘 Pts w/ SLE nephritis Class III/IV ± 5
🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids)
📊 Obi: ⇡rate of renal response and improved renal outcomes

#LupusNephritis #RheumSky #NephSky #MedSky #Lupus

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving stan...

Efficacy and Safety of #Obinutuzumab in Active #Lupus #Nephritis

New #anti-CD20 monoclonal antibody on the horizon in lupus nephritis?

www.nejm.org/doi/full/10....

Obinutuzumab: Efectos, Usos y Últimos Avances en el Tratamiento de Cáncer ¿Qué es el Obinutuzumab y cómo funciona en el tratamiento del cáncer? El Obinutuzumab es un anticuerpo monoclonal diseñado específicamente para tratar ciertos tipos de cáncer, especialmente los linfomas y leucemias. Se clasifica como... The post…

Obinutuzumab: Efectos, Usos y Últimos Avances en el Tratamiento de Cáncer #Obinutuzumab #Cáncer #TratamientoCáncer

#Obinutuzumab and #Ofatumumab are More Effective Than Rituximab in the Treatment of #MembranousNephropathy Patients With Anti-Rituximab Antibodies

#VisualAbstract by @priti899

www.kireports.org/ar...

Lovely catching up with Carsten Niemann on the GLOW study 64-month follow-up: #ibrutinib + #venetoclax outperforms #chlorambucil + #obinutuzumab in elderly/comorbid patients 🩸🔦

Stay tuned for the full video www.vjhemonc.com/event/ash-20... 👀

@ash-hematology.bsky.social #ASH24 #CLL